Molecule News and Research

RSS

Repros Therapeutics amends its existing license for Proellex

Repros Therapeutics today announced that the Company has entered into an amendment with the National Institutes of Health (NIH) to its existing exclusive license for Proellex® that revises the existing milestones and dates for performance to provide additional time to lift the current clinical hold on Proellex or select a second generation molecule for further development from the family of anti-progestational agents covered by the license.

29 Oct 2009

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The $308,000 grant will be used to advance certain small molecule drug discovery programs designed to correct the genetic mutation most common to cystic fibrosis (CF).

28 Oct 2009

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

Veeva CRM to be implemented at Adamas Pharmaceuticals

Adamas Pharmaceuticals, an emerging pharmaceutical company focused on developing small-molecule therapeutics to treat neurological and infectious diseases, selected Veeva System’s VBioPharma™ KOL Edition – part of the Veeva CRM suite. Selection of Veeva’s SaaS solution marks an important step in Adamas’ early-stage product commercialization strategy.

28 Oct 2009

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

28 Oct 2009

Rutgers scientist receives 2009 Gruber International Research Award

For the first time, it now is possible for researchers to peer into those internal processes in a rodent brain. Eva Pastalkova, a post-doctoral researcher at the Center for Molecular and Behavioral Neuroscience at Rutgers University, Newark and her advisor, Professor Gy-rgy Buzsaki, have developed a method for studying internally generated brain activity in rats.

28 Oct 2009

Ohio State University researchers first to observe real-time behavior of the Dpo4 enzyme

Scientists here have identified how the motions of an enzyme are related to correctly copying genetic instructions, setting the stage for studies that can uncover what happens when DNA copying mistakes are made.

28 Oct 2009

Starting Grant from ERC to LMU junior researchers

Two junior researchers from Ludwig-Maximilians-Universit-t (LMU) in Munich shall each receive a Starting Grant from the European Research Council (ERC). Professor Jens Michaelis, Department of Chemistry and Biochemistry, and Privatdozent Dr. David V-hringer, Institute of Immunology, shall receive grants amounting to 1.4 and 1.7 million Euros over five years. With its Starting Grant, the ERC supports highly creative researchers in order to encourage pioneering frontier research.

27 Oct 2009

Helicos Biosciences reports operational highlights for the third quarter of 2009

Helicos BioSciences Corporation announced today its operational, technical and scientific highlights for the quarter ended September 30, 2009.

27 Oct 2009

Arizona State University researchers to use laws of physics for cancer research

Instead of killing cancer cells, researchers at Arizona State University will use the laws of physics to figure out how to control them. And, rather than treating cancer as a disease and seeking a cure, ASU scientists will view cancer cells as physical objects and study them the way a physicist would, using simple variables like temperature, pressure and force.

27 Oct 2009

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced issuance of Japanese Patent Number: 4354633, titled, "Hypoxia regulated genes," on August 7, 2009.

27 Oct 2009

Discovery of molecular pathway in brain may reverse cognitive impact of sleep deprivation

A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.

27 Oct 2009

Protein crucial for insulin regulation may play a role in diabetes

A cellular protein from a family involved in several human diseases is crucial for the proper production and release of insulin, new research has found, suggesting that the protein might play a role in diabetes.

27 Oct 2009

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

27 Oct 2009

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. project manager Dr. Yossef Kliger provided an overview of Compugen’s DAC Blockers Platform and reviewed disease model data for selected product candidates.

26 Oct 2009

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Napo Pharmaceuticals, Inc. has in-licensed from the University of California Regents additional small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor technology including gastrointestinal (GI) and polycystic kidney disease (PKD) indications.

26 Oct 2009

Japanese Patent granted for Pharmalink AB's Nefecon

Pharmalink AB announced today that it has been granted Japanese Patent No 4326696, "Methods and means for treating glomerulonephritis" for its product Nefecon(R) which is being developed to treat IgA nephropathy, a glomerulonephritis leading to end-stage renal disease (ESRD). Counterparts of the patent have been issued for other territories including the EU, US and China.

26 Oct 2009

Enzyme Mst3b is essential for regenerating damaged axons in live animal model, say researchers

Researchers at Children's Hospital Boston report that an enzyme known as Mst3b, previously identified in their lab, is essential for regenerating damaged axons (nerve fibers) in a live animal model, in both the peripheral and central nervous systems.

26 Oct 2009

APC enzyme may be effective for treating amyotrophic lateral sclerosis

A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice. The results offer a bit of good news in efforts to develop a therapy to stop or slow the progression of a disease that generally kills its victims within just a few years.

26 Oct 2009

Guidance for Quick-Med Technologies’ NIMBUS barrier gauze wound dressings issued

Quick-Med Technologies, Inc. announced today that the Food and Drug Administration has issued Guidance to support the classification of the Company’s NIMBUS® barrier gauze wound dressings as Class II medical devices.

23 Oct 2009

Molecule News and Research

Repros Therapeutics amends its existing license for Proellex

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Veeva CRM to be implemented at Adamas Pharmaceuticals

Successful partnership between Mercury Therapeutics and CreaGen Biosciences highlighted

Rutgers scientist receives 2009 Gruber International Research Award

Ohio State University researchers first to observe real-time behavior of the Dpo4 enzyme

Starting Grant from ERC to LMU junior researchers

Helicos Biosciences reports operational highlights for the third quarter of 2009

Arizona State University researchers to use laws of physics for cancer research

Quark Pharmaceuticals receives a Japanese patent for its hypoxia regulated genes

Discovery of molecular pathway in brain may reverse cognitive impact of sleep deprivation

Protein crucial for insulin regulation may play a role in diabetes

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Japanese Patent granted for Pharmalink AB's Nefecon

Enzyme Mst3b is essential for regenerating damaged axons in live animal model, say researchers

APC enzyme may be effective for treating amyotrophic lateral sclerosis

Guidance for Quick-Med Technologies’ NIMBUS barrier gauze wound dressings issued

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News